Board and Management

Tim Lovell, PhD, MBA, GAICD: Tim is the founding Board Chairman and CEO of Calpain Therapeutics. Tim has led the acquisition and development of the current ophthalmic pipeline, and has been instrumental in securing finance for the development. He is an author of numerous scientific publications, an invited and accomplished speaker, and an internationally-renowned molecular modeller in the pharmaceutical (AstraZeneca) and not-for-profit biotech (Scripps Research Institute). Tim holds a PhD in Theoretical Quantum Chemistry and Molecular Modelling, an MBA specialising in entrepreneurial ventures, is a graduate of the Australian Institute of Company Directors and a member of the local Biotechnology Angels Group.

Hugo LeMessurier BSc(Hons), GAICD: Hugo is a Non-Executive Director, and an experienced entrepreneurial business leader with a proven track record of successfully implementing complex business solutions within an international environment. His expertise has assisted the building of sustainable small-to-medium enterprise (SME) businesses via strategic planning, sales and marketing, international business development and public company listing. For over a decade Hugo has held directorships and senior management positions in start-up, listed and multinational organisations in the USA, EU and Australia. He has worked in the biotechnology industry for over 20 years including 8 years in the USA and EU with Genzyme Corporation in senior sales and marketing positions. He regularly advises biotechnology companies and research organisations on technology commercialisation, licensing and partnering strategies. He holds a BSc in microbiology, immunology and genetics, is a Director of Cryptogen Pty Ltd, Director of Axxos Pty Ltd, Growth Mentor Pty Ltd, a member of the Australian Institute of Company Directors, AusBiotech, Australian Angel investment groups and is an active investor in early stage companies.

Wayne Irvine: Wayne is an Observer to the Board, and a founding owner / director of the Westside Group of companies operating in the commercial and industrial construction and facility management industry.  Specializing in building services his business units offer preventative maintenance, service, design and construction solutions in air-conditioning / mechanical and plumbing services.  The Westside team has over one hundred staff with an annual turnover in excess of 40 million dollars. He is a certified Mediator and an Adjudicator for South Australia’s Security of Payment Act. More than 20 years of senior business management together with formal training and practical experience has provided Wayne with a passion to share a wealth of developed intellectual property with likeminded business people and entrepreneur’s.  Following an investment through his involvement with a South Australian Angels Group, Wayne sits as an observer on the board for Calpain Therapeutics Pty. Ltd. representing his group of investors. 

Matthew Worrell, CPA: Matthew is the company Secretary and founded Worrell & Co in 2003 and has been working in the accounting industry for the last 21 years. He is a certified practising accountant and specialises in business consulting, self-managed super funds and taxation.

Scientific Advisory

Professor Andrew Abell, PhD: Andrew is Co-Founder and Principal Scientific Advisor to Calpain Therapeutics and was the chemistry inventor of the proprietary class of compounds that Calpain Therapeutics holds in its portfolio. Andrew is also Professor of Chemistry at Adelaide University, Australia. He is an expert on the design and synthesis of protease inhibitors, author of more than 140 peer–reviewed publications and three patents, and he has led research grants totalling more than $10 million in the last 10 years. His international standing has been recognised with the award of the NZIC Easterfield medal and his being an elected Fellow of the New Zealand Institute of Chemistry and the Royal Australian Institute of Chemistry, a member of the Australian Research Council College of Experts, and the award of adjunct Professorships with the University of Canterbury and Lincoln University.  Andrew is an Editor of international chemistry journals and two books on peptidomimetics and he provides 20 years of continuous research support for design and synthesis of protease inhibitors and other therapeutic agents.

Business Advisory

Professor Evan Siegel, PhD: Dr. Siegel founded Ground Zero Pharmaceuticals (GZP) in 1999 from his consulting firm, Ground Zero Strategics, Ltd.  Dr. Siegel has held positions as a Toxicology Reviewer at the US Food and Drug Administration and Food and Drug Branch, California Department of Health Services and, at the latter, was Supervising Toxicologist and Chief of Special Services. He has served in regulatory affairs and executive positions in both the pharmaceutical industry (Astra, Syntex, Medical Science Systems and OXO Chemie) and trade association environments. He attended the Waksman Institute of Microbiology where he earned both his Master and Doctor of Philosophy degrees in Virology and Molecular Biology. He is an Adjunct Professor in the Centre for Integrated Preclinical Drug Development, University of Queensland, Australia. Dr. Siegel is the Chairman of the GZP Board of Directors.

Andrew Bollen, PhD: Andrew Bollen was most recently an Executive Director at Playford Capital Pty Ltd. He has worked in high technology research and development, start-up management, investment banking, portfolio management, and venture investing in Australia, the United States, and Asia. He has played a key role in raising substantial funds for start-ups, serving on their boards, helping to manage their growth and structuring and negotiating public and private transactions. Andrew is a Director of Cavitus Pty Ltd, Embertec Pty Ltd, NVT Systems Pty Ltd, and Reproductive Health Science Pty Ltd. He holds a PhD in Artificial Intelligence from The Australian National University and also a BSc from The University of Adelaide.

Ophthalmology Advisory

Professor Robert Casson, MBBS (Hons), DPhil, FRANZCO: Professor Bob Casson is a Cataract and Glaucoma (Neuroprotection) surgeon, co-Director of the Royal Adelaide Hospital Ophthalmology Unit, a Scientific Advisory Board member to Allergan, Editor-in-Chief of Clinical and Experimental Ophthalmology, an internationally-renowned expert in Glaucoma and a Board member for the Sight-For-All Charity. 

Dr. James Muecke, MBBS (Hons), FRANZCO: Dr. James Muecke is a Cataract and Ocular Oncology surgeon -  the Sight-For-All Charity’s founding Chairman and an internationally recognised Cataract Ophthalmologist. Very recently, James was the recipient of an award from the Australia Pacific Ophthalmology Association for services to cataract surgery in preventing blindness in developing countries.

Dr. Graham Fraenkel, BMBS FRACS FRANZCO: Dr. Graham Fraenkel is a Cataract surgeon, a Fellow of the Royal Australasian College of Surgeons and a Fellow of the Royal Australian and New Zealand College of Ophthalmologists. Dr Fraenkel is a member of the American Society of Cataract and Refractive Surgeons. He has been a Senior Clinical Lecturer with the University of Adelaide teaching cataract and corneal surgery. Dr Fraenkel special interests are in the areas of cataract surgery, refractive & corneal surgery. He has published an impressive list of academic papers and participated in a number of research projects. Dr Fraenkel has also established an enviable reputation as a lecturer. Dr Fraenkel was the first Ophthalmologist in Australia to join The Fred Hollows Foundation’s International Mentoring and Fund Raising Programme.  

Pharmaceutical / Regulatory / Toxicology / Formulation Advisory

Des Williams, PhD: Dr. Des Williams has had a total of 23 years in the pharmaceutical industry in various roles, which has included seven years in the Research and Development Group, Faulding Pharmaceuticals, and many consultancies in the pharmaceutical industry in Australia and various international jurisdictions, including the CSIRO. His research work has focused on understanding the biochemical basis and dietary factors of colorectal cancer (in collaboration with CSIRO), formulation of new pharmaceutical compounds and their evaluation (preclinical and clinical). Des is a member of the Pharmaceutical Subcommittee, Advisory Committee for Prescription Medicines, within the Therapeutic Goods Administration (TGA) in Canberra.  

Rae West, PhD: Rae West is a highly-trained clinical research professional with range of skills developed during 20+ years working in the pharmaceutical, biotechnology and clinical consulting industries. She has successfully managed all phases of clinical trials conducted at Australian and overseas investigational sites, including Contract Research Organisation (CROs), planning, monitoring and reporting of First-in-Human (FIH) Phase I and bioequivalence/bioavailability (BE/BA) studies. She has trained professionals to internationally recognised regulatory and ethical standards required to conduct trials using procedures in compliance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines. Her experience covers Food and Drug Administration (FDA) meeting submissions with knowledge of the preclinical toxicology and safety pharmacology studies required to support initial human trials of new chemical (molecular) entities.